IDH2 and acute myeloid leukemia: Enasidenib, an IDH2 inhibitor, and ivosidenib (or AG-120), an IDH1 inhibitor, were approved by the FDA in 2017 and 2018, respectively, with an indication for IDH-mutated AML [29,87].